Literature DB >> 8787146

Corticobasal degeneration with neither argyrophilic inclusions nor tau abnormalities: a new subgroup?

K Kawasaki1, K Iwanaga, K Wakabayashi, M Yamada, H Nagai, J Idezuka, Y Homma, F Ikuta.   

Abstract

In corticobasal degeneration (CBD), cerebral cortical neuronal loss with achromasia and degeneration of the subcortical nuclei, particularly the substantia nigra, are common. Recent studies have suggested that the occurrence of argyrophilic nigral inclusions, resembling the neurofibrillary tangles found in progressive supranuclear palsy, and widespread tau abnormalities may be features of CBD. We studied brain tissues from two patients in whom CBD was suspected clinically. From the distribution of their cortical and subcortical lesions, the patients were diagnosed as having CBD. However, Gallyas/tau-positive neuronal and glial structures were not found, which suggests there may be a subgroup of CBD with neither argyrophilic inclusions nor tau abnormalities.

Entities:  

Mesh:

Year:  1996        PMID: 8787146     DOI: 10.1007/s004010050405

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  31 in total

1.  Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia.

Authors:  G Wightman; V E Anderson; J Martin; M Swash; B H Anderton; D Neary; D Mann; P Luthert; P N Leigh
Journal:  Neurosci Lett       Date:  1992-05-25       Impact factor: 3.046

2.  Ballooned neurons in several neurodegenerative diseases and stroke contain alpha B crystallin.

Authors:  J Lowe; D R Errington; G Lennox; I Pike; I Spendlove; M Landon; R J Mayer
Journal:  Neuropathol Appl Neurobiol       Date:  1992-08       Impact factor: 8.090

Review 3.  Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles.

Authors:  W Paulus; M Selim
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

4.  Large neurons in the neostriatum in Alzheimer's disease and progressive supranuclear palsy: a topographic, histologic and ultrastructural investigation.

Authors:  K Oyanagi; H Takahashi; K Wakabayashi; F Ikuta
Journal:  Brain Res       Date:  1991-03-29       Impact factor: 3.252

5.  Corticonigral degeneration with neuronal achromasia presenting with primary progressive aphasia: ultrastructural and immunocytochemical studies.

Authors:  K Arima; H Uesugi; I Fujita; Y Sakurai; S Oyanagi; S Andoh; Y Izumiyama; T Inose
Journal:  J Neurol Sci       Date:  1994-12-20       Impact factor: 3.181

6.  Comparative immunohistochemical study on the expression of alpha B crystallin, ubiquitin and stress-response protein 27 in ballooned neurons in various disorders.

Authors:  S Kato; A Hirano; T Umahara; M Kato; F Herz; E Ohama
Journal:  Neuropathol Appl Neurobiol       Date:  1992-08       Impact factor: 8.090

7.  Corticodentatonigral degeneration with neuronal achromasia.

Authors:  J J Rebeiz; E H Kolodny; E P Richardson
Journal:  Arch Neurol       Date:  1968-01

8.  Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases.

Authors:  P Giannakopoulos; P R Hof; C Bouras
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy.

Authors:  H Mori; M Nishimura; Y Namba; M Oda
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Dementia of frontal lobe type: neuropathology and immunohistochemistry.

Authors:  D M Mann; P W South; J S Snowden; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

View more
  1 in total

1.  Clustering and spatial correlations of the neuronal cytoplasmic inclusions, astrocytic plaques and ballooned neurons in corticobasal degeneration.

Authors:  R A Armstrong; N J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2009-06-24       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.